Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15432939 | 0.91 | CA2 (0.36) | POLBALDH1A1HSD17B10HPGDKDM4E | |
| SCHEMBL19002243 | 0.87 | ALDH1A1 (0.43) | POLBALDH1A1HSD17B10HPGDKDM4E | |
| SCHEMBL15071692 | 0.85 | ALDH1A1 (0.44) | POLBALDH1A1HSD17B10HPGDKDM4E | |
| SCHEMBL30497478 | 0.83 | ALDH1A1 (0.46) | POLBALDH1A1HSD17B10HPGDKDM4E | |
| SCHEMBL18997638 | 0.82 | POLB (0.32) | POLBHSD17B10BLMPMP22CA2 | |
| SCHEMBL10305060 | 0.81 | MLYCD (0.40) | POLBALDH1A1HPGDKDM4EGAA | |
| SCHEMBL3628031 | 0.79 | POLB (0.41) | POLBALDH1A1HSD17B10HPGDKDM4E | |
| SCHEMBL16355256 | 0.79 | ALDH1A1 (0.40) | POLBALDH1A1HSD17B10HPGDKDM4E | |
| SCHEMBL3197871 | 0.77 | NR1I2 (0.41) | POLBALDH1A1HSD17B10HPGDKDM4E | |
| SCHEMBL23502942 | 0.77 | POLB (0.39) | POLBALDH1A1HSD17B10HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639413-B2 | Polymerizable composition for optical materials and application of same | MITSUI CHEMICALS, INC. (JP) | 2023-05-02 | — | — | US | disclosed |
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | POLB 1589/4885ALDH1A1 2765/4885HSD17B10 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.